Can better testing unlock the secrets of a rare lung disease?

NCT ID NCT03704207

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at how well current tests, including a simple breath test called nasal nitric oxide (nNO) testing, can diagnose Primary Ciliary Dyskinesia (PCD), a rare genetic condition that affects the lungs and sinuses. Researchers will collect and analyze data from people over age 2 who are referred for PCD testing. The goal is to see how often these tests are used and how helpful they are in making a clear diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help refine and improve the diagnostic process for PCD, leading to faster and more accurate diagnoses.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly improve patient health. The results may not change current clinical practice if the tests prove unreliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Vanderbilt Children's hospital

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.